Harpoon Therapeutics stock (US4135961044): takeover by Merck reshapes prospects for cancer drug developer

Harpoon Therapeutics is being acquired by Merck in an all?cash deal that values the cancer?focused biotech above its pre?announcement trading levels and follows mixed clinical updates. What the transaction means for the stock and its pipeline focus.

Harpoon Therapeutics is in the spotlight after announcing a definitive agreement to be acquired by Merck in an all?cash transaction that follows a series of clinical updates in its oncology pipeline, according to a company press release published on 01/08/2024 and a Merck statement on the same day Harpoon Therapeutics IR as of 01/08/2024 and Merck news as of 01/08/2024.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Harpoon Therapeutics
• Sector/industry: Biotechnology, oncology
• Headquarters/country: South San Francisco, United States
• Core markets: US and global oncology drug markets
• Key revenue drivers: Potential future licensing and milestone payments from immuno?oncology therapies
• Home exchange/listing venue: Nasdaq (ticker: HARP)
• Trading currency: US dollar (USD)

Harpoon Therapeutics: core business model

Harpoon Therapeutics is a clinical?stage biotechnology company focused on developing novel T?cell engagers and immune?modulating therapies for cancer. The company does not yet generate material product revenue and instead relies on research collaborations, milestone payments, and external funding, a pattern typical for early?stage oncology specialists in the US biotech sector.

The core of Harpoon Therapeutics’ strategy is to design molecules that bring a patient’s own immune cells into direct contact with tumor cells to trigger targeted cell killing. This approach aims to harness the power of T?cells while trying to manage the safety issues that have historically limited earlier generations of T?cell–engaging therapies.

Harpoon Therapeutics has positioned its platform as a potentially differentiated way to expand T?cell engager technology into solid tumors, which are traditionally more difficult to treat with immunotherapies than blood cancers. Its pipeline includes several candidates targeting different tumor antigens, and before the Merck transaction the company’s value depended largely on the clinical progress and partnering potential of these assets.

Main revenue and product drivers for Harpoon Therapeutics

Because Harpoon Therapeutics is still in the clinical stage, potential future revenue is tied to the success of its lead product candidates and to collaboration agreements with larger pharmaceutical partners. The lead programs have been developed for difficult?to?treat cancers, where successful drugs can often achieve premium pricing and broad uptake in the US and other major markets, according to company pipeline overviews and investor presentations published in 2023 and 2024 Harpoon Therapeutics IR as of 11/09/2023.

Harpoon Therapeutics’ business model has been to advance its molecules through early? and mid?stage clinical trials to establish safety and signs of efficacy, then either continue development independently or partner with larger companies. Under such partnerships, it may receive upfront payments, research funding, and milestones, with possible royalties if products reach the market. This creates a highly binary revenue outlook: positive trial data or licensing deals can significantly enhance value, while setbacks can weigh heavily on the share price.

In the context of the Merck acquisition, these drivers remain relevant because Merck is effectively acquiring Harpoon Therapeutics’ platform and pipeline potential. For existing shareholders, the all?cash consideration crystallizes value at a defined level, while future upside from successful drug launches is expected to accrue mainly to the combined company rather than to Harpoon Therapeutics as an independent stock.

Conclusion

The planned acquisition of Harpoon Therapeutics by Merck underscores the strategic interest of large pharmaceutical companies in innovative T?cell engager platforms. For the stock, the deal places a clear valuation marker on the company’s clinical pipeline and reduces the typical volatility associated with standalone small?cap biotech names. At the same time, the transaction highlights both the promise and risk of early?stage oncology R&D, where future cash flows depend on clinical success, regulatory outcomes, and competitive dynamics. For US?focused investors following the sector, Harpoon Therapeutics now mainly serves as an example of how platform?based biotech companies can become acquisition targets once their science reaches a certain level of maturity.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.